<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221017056214N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-02</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effectiveness of mouthwash containing green tea extract and pomegranate peel, with and without zinc, compared to 0.12% chlorhexidine mouthwash on gingivitis in patients with gingivitis or mild chronic periodontitis: a double-blind randomized clinical trial</public_title>
      <acronym>CHX MW</acronym>
      <scientific_title>Investigating the effectiveness of mouthwash containing green tea extract and pomegranate peel, with and without zinc, compared to 0.12% chlorhexidine mouthwash on gingivitis in patients with gingivitis or mild chronic periodontitis: a double-blind randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>105</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66381</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: So far, no study examines the synergistic effect of these two effective ingredients of green and pomegranate tea in control and improvement of periodontal diseases. Also, in previous studies, the effectiveness of zinc as a potent antioxidant has not been addressed to control the periodontal diseases, hence, we had an anti-inflammatory effect of mouthwash containing green tea extract and mouthwashes containing green tea extract_ zinc in We compared the prevention and improvement of periodontal diseases, Randomization description: Random allocation was based on 6 random blocks, whose sequence list was determined by Random Allocation Software and placed in three groups, Blinding description: Allocation concealment method was used in order to avoid the selection bias error (Information Bias). In this way, the number 1 to 35 was written on each envelope. In each envelope, based on the random numbers obtained, one of Three letters B, A and C were written and finally 35 envelopes were given to the second researcher. After the initial measurement of the indicators, the second researcher gave the corresponding mouthwash to the patients based on the number of patients written on the envelope and the intervention written inside the envelope. And they explained to the patients how to use it.In this study, researchers were blinded. In this way, the mouthwashes were packed in white opac bottles of the same size, so that the bottles cannot be distinguished from each other in terms of appearance. Only on the bottle of one of the three letters B, A and C, the pharmacist producing the mouthwashes was asked to write the content of each mouthwash in a closed letter and this letter should not be opened until the end of the study. Patients were not blinded in this study. For concealment, this list was kept in a sealed envelope in the research center or in the dental clinic office.</study_design>
      <phase>3</phase>
      <hc_freetext>Mild chronic gingivitis or periodontitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: patients in a questionnaire based on the block sequence list, in one of groups A (mouthwash containing pomegranate peel extract and green tea, with zinc), B (mouthwash containing pomegranate peel extract and green tea, without zinc) and C (  chlorhexidine mouthwash 0.12%) and received the corresponding mouthwash.  Group A was the intervention;  The people of this group were given green tea extract - pomegranate peel - zinc mouthwash.  Group B was the same as the second intervention group, this group was given green tea extract-pomegranate skin mouthwash. Intervention 2: Intervention group:  group C (the third group), which is the control group, was given 0.12% chlorhexidine.  All patients were asked to use the given mouthwash (green tea extract-pomegranate peel-zinc mouthwash for group A, green tea extract extract-pomegranate peel mouthwash for group B and chlorhexidine 0.12% for group C) twice a day for two weeks.  (after brushing teeth) use 10 ml of mouthwash each time. and if using mouthwash, record and report its consumption as follows.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The final decision is not yet known</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bardia vadiati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Academic Complex of Gilan University of Medical Sciences, Department of Periodontology,In front of Khazar</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4194173774</zip>
        <telephone>0981333486406</telephone>
        <email>Dr.bardia_vad@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bardia vadiati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Academic Complex of Gilan University of Medical Sciences, Department of Periodontology,In front of Khazar and Padideh restaurants,2 km to Fuman,Saravan belt,The end of the Lacan road,gas field</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4194173774</zip>
        <telephone>0981333486407</telephone>
        <email>Dr.bardia_vad@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having at least 20 natural teeth
Suffering from gingivitis or mild chronic periodontitis
Loss of clinical connections less than or equal to 2 mm
Probe depth less than or equal to 3 mm will be included in the study</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergic reaction to pomegranate
Systemic diseases such as diabetes mellitus
Pregnant and lactating women
Cigarette or tobacco user
Taking antibiotics or non-steroidal anti-inflammatory drugs in the 6 months before the study
History of receiving periodontal interventions in the 6 months before the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>,K05.10</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic gingivitis, plaque induced</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: patients in a questionnaire based on the block sequence list, in one of groups A (mouthwash containing pomegranate peel extract and green tea, with zinc), B (mouthwash containing pomegranate peel extract and green tea, without zinc) and C (  chlorhexidine mouthwash 0.12%) and received the corresponding mouthwash.  Group A was the intervention;  The people of this group were given green tea extract - pomegranate peel - zinc mouthwash.  Group B was the same as the second intervention group, this group was given green tea extract-pomegranate skin mouthwash.</i_keyword>
      <i_keyword>Intervention group:  group C (the third group), which is the control group, was given 0.12% chlorhexidine.  All patients were asked to use the given mouthwash (green tea extract-pomegranate peel-zinc mouthwash for group A, green tea extract extract-pomegranate peel mouthwash for group B and chlorhexidine 0.12% for group C) twice a day for two weeks.  (after brushing teeth) use 10 ml of mouthwash each time. and if using mouthwash, record and report its consumption as follows.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Measuring the PBI index of the gingival groove is probed by using the Michigan O probe with Williams marking, in walking mode.  30 seconds after probing the gingival groove, the presence or absence of bleeding in 3 points on the buccal surface (mesiobuccal, midbuccal and distobuccal) and 3 points on the lingual surface (mesiolingual, midlingual and distolingual) will be checked and recorded. The number of bleeding areas will be calculated and this index will be reported as the percentage of bleeding dental surfaces compared to the total dental surfaces.MGI index of inflammation, color change and gum contour change will be checked in 6 points around all teeth.  3 points on the buccal level (mesiobuccal, midbuccal and distobuccal) and 3 points on the lingual level (mesiolingual, midlingual and distolingual) are evaluated and each one will be given a score from 0 to 4. So that score 0 is without inflammation;  score 1, the presence of mild inflammation with a slight change in color and contour in parts of the gum;  score 2, the presence of mild inflammation in the entire gum;  Score 3 means moderate inflammation and score 4 means severe inflammation.  The average of the obtained numbers will be calculated and reported.  To measure the PI index, patients are asked to chew Fushin tablets for 60 seconds and then rinse their mouths.  Stained surfaces will be considered as positive surfaces.  Unpainted surfaces are considered as negative surfaces.  Staining or not staining will be evaluated at 4 points including midbuccal, mesial papillae, midlingual and distal papillae. This index is reported as the percentage of stained areas compared to the total tooth surfaces. Timepoint: Indicators are measured 2 weeks after using the mouthwash. Method of measurement: MGI index and PI index are clinically evaluated based on the indices.  30 After exploring the gingival groove, the presence or absence of presence is checked.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Paid in person.</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-31</approval_date>
        <contact_name>Ethics Committee of Gilan University of Medical Sciences</contact_name>
        <contact_address>Sardar Soleimani's dormitory,Kargar alley 1,Lacan Blvd Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
